Article Text

Download PDFPDF
Obesity-related glomerulopathy: another nail in the coffin of the epidemic of end-stage renal disease
  1. Mohamed H Ahmed1,
  2. Atif A Khalil2
  1. 1Department of Chemical Pathology, Southampton General Hospital, Southampton, UK
  2. 2Department of Nephrology, Royal Liverpool University Hospital, Liverpool, UK
  1. Correspondence to:
 Dr M H Ahmed
 Department of Chemical Pathology, Mail point 6, Level D South Academic Block, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK;elziber{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The clustering of insulin resistance, dysglycaemia, dyslipidaemia, hypertension and central obesity represents the major features of metabolic syndrome. These clusters of factors may share common aetiology, each of which is a risk factor for cardiovascular disease. The metabolic syndrome seems to affect between 10% and 25% of adult populations worldwide. Several studies have described the association between metabolic syndrome, and diabetes and cardiovascular disease.1 Although obesity is often associated with diabetes and hypertension, which are two of the most common risk factors for the development of end-stage renal disease (ESRD), it has been suggested that obesity in itself is an independent risk factor.

The prevalence of obesity-related glomerulopathy …

View Full Text


  • Competing interests: None declared.